Cetuximab for the Treatment of Colorectal Cancer
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cetuximab, an IgG1 chimeric monoclonal antibody against epidermal growth factor receptor (EGFR), has activity against colorectal cancers that express EGFR. METHODS: From December 2003 to August 2005, 572 patients who had colorectal cancer expressing immunohistochemically detectable EGFR and who had been previously treated with a fluoropyrimidine, irinotecan, and oxaliplatin or had contraindications to treatment with these drugs underwent randomization to an initial dose of 400 mg of cetuximab per square meter of body-surface area followed by a weekly infusion of 250 mg per square meter plus best supportive care (287 patients) or best supportive care alone (285 patients). The primary end point was overall survival. RESULTS: In comparison with best supportive care alone, cetuximab treatment was associated with a significant improvement in overall survival (hazard ratio for death, 0.77; 95% confidence interval [CI], 0.64 to 0.92; P=0.005) and in progression-free survival (hazard ratio for disease progression or death, 0.68; 95% CI, 0.57 to 0.80; P<0.001). These benefits were robust after adjustment in a multivariable Cox proportional-hazards model. The median overall survival was 6.1 months in the cetuximab group and 4.6 months in the group assigned to supportive care alone. Partial responses occurred in 23 patients (8.0%) in the cetuximab group but in none in the group assigned to supportive care alone (P<0.001); the disease was stable in an additional 31.4% of patients assigned to cetuximab and in 10.9% of patients assigned to supportive care alone (P<0.001). Quality of life was better preserved in the cetuximab group, with less deterioration in physical function and global health status scores (both P<0.05). Cetuximab treatment was associated with a characteristic rash; a rash of grade 2 or higher was strongly associated with improved survival (hazard ratio for death, 0.33; 95% CI, 0.22 to 0.50; P<0.001). The incidence of any adverse event of grade 3 or higher was 78.5% in the cetuximab group and 59.1% in the group assigned to supportive care alone (P<0.001). CONCLUSIONS: Cetuximab improves overall survival and progression-free survival and preserves quality-of-life measures in patients with colorectal cancer in whom other treatments have failed. (ClinicalTrials.gov number, NCT00079066 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cetuximab is a chimeric (mouse/human) monoclonal IgG1 antibody developed to bind the extracellular EGFR domain that blocks dimerization and ligand-induced signaling of the EGFR pathway [14].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [14]
In the citing paper
“Patients who received cetuximab had a 6.1-month median survival compared with 4.6 months among individuals in the best supportive care group.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [14]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Self-citationGoldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259
Research works printed but not linked: 3
- Mellstedt H, 2003, Drugs Today (Barc), 39, 1
- Eng C, 2007, J Clin Oncol, 25, 18s
- Van Cutsem E, 2007, J Clin Oncol, 25, 18s
Cited by
Items 101–200 of 1,001
Karlsson, H., Fryknäs, M., Larsson, R., & Nygren, P. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.03.026 · Cited by 180
S3-Leitlinie Kolorektales Karzinom Version 1.0 - Juni 2013 AWMF-Registernummer: 021/007OL
Pox, C., Aretz, S., Bischoff, S., Graeven, U., Hass, M., Heußner, P., Hohenberger, W., Holstege, A., Hübner, J., Kolligs, F., et al. (2013) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0033-1350264 · Cited by 179
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
Cappuzzo, F., Varella-Garcia, M., Finocchiaro, G., Skokan, M., Gajapathy, S., Carnaghi, C., Rimassa, L., Rossi, E., Ligorio, C., Di Tommaso, L., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604439 · Cited by 178
Role of Epidermal Growth Factor Receptor (EGFR) and Its Ligands in Kidney Inflammation and Damage
Rayego-Mateos, S., Rodrigues-Diez, R., Morgado-Pascual, J. L., Valentijn, F., Valdivielso, J. M., Goldschmeding, R., & Ruiz-Ortega, M. (2018) · Mediators of Inflammation · doi:10.1155/2018/8739473 · Cited by 175
“Among the developed antibodies, cetuximab stands out, which improved the survival rates in patients with lung cancer and colorectal cancer in combination with chemotherapy [264, 265].”
BackgroundBRAF V600E mutation-specific antibody: A review
Ritterhouse, L. L., & Barletta, J. A. (2015) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2015.02.010 · Cited by 172
“Anti-EGFR therapy with agents such as cetuximab has become standard treatment for patients with advanced CRC.72 While results are conflicting, there is some indication that BRAF mutation may correlate with resistance to the anti-EGFR therapy.73 Thus, identification of a BRAF mutation is an established clinical tool to…”
BackgroundInfluentialMonoclonal antibodies in the treatment of metastatic colorectal cancer: A review
Tol, J., & Punt, C. J. A. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.03.012 · Cited by 176
Personeni, N., Fieuws, S., Piessevaux, H., De Hertogh, G., De Schutter, J., Biesmans, B., De Roock, W., Capoen, A., Debiec-Rychter, M., Van Laethem, J.-L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0449 · Cited by 174
Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases
Hafeez, U., Gan, H. K., & Scott, A. M. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.05.010 · Cited by 176
The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs
Niraula, S., Seruga, B., Ocana, A., Shao, T., Goldstein, R., Tannock, I. F., & Amir, E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.3824 · Cited by 167
Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial
Jonker, D. J., Nott, L., Yoshino, T., Gill, S., Shapiro, J., Ohtsu, A., Zalcberg, J., Vickers, M. M., Wei, A. C., Gao, Y., et al. (2018) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(18)30009-8 · Cited by 172
Self-citationDahabreh, I. J., Terasawa, T., Castaldi, P. J., & Trikalinos, T. A. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-1-201101040-00006 · Cited by 172
Hickish, T., Andre, T., Wyrwicz, L., Saunders, M., Sarosiek, T., Kocsis, J., Nemecek, R., Rogowski, W., Lesniewski-Kmak, K., Petruzelka, L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30006-2 · Cited by 164
Antibody therapeutics and immunoregulation in cancer and autoimmune disease
Yasunaga, M. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.001 · Cited by 169
Peeters, M., Kafatos, G., Taylor, A., Gastanaga, V. M., Oliner, K. S., Hechmati, G., Terwey, J.-H., & van Krieken, J. H. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.05.017 · Cited by 163
Protease‐activated prodrugs: strategies, challenges, and future directions
Poreba, M. (2020) · The FEBS Journal · doi:10.1111/febs.15227 · Cited by 160
Acquired resistance to EGFR‐targeted therapies in colorectal cancer
Van Emburgh, B. O., Sartore-Bianchi, A., Di Nicolantonio, F., Siena, S., & Bardelli, A. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.003 · Cited by 160
Karapetis, C. S., Jonker, D., Daneshmand, M., Hanson, J. E., O'Callaghan, C. J., Marginean, C., Zalcberg, J. R., Simes, J., Moore, M. J., Tebbutt, N. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0606 · Cited by 159
Self-citationKRAS and BRAF: drug targets and predictive biomarkers
Vakiani, E., & Solit, D. B. (2011) · The Journal of Pathology · doi:10.1002/path.2796 · Cited by 162
Dillman, R. O. (2011) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2010.0902 · Cited by 205
Schmiegel, W., Scott, R. J., Dooley, S., Lewis, W., Meldrum, C. J., Pockney, P., Draganic, B., Smith, S., Hewitt, C., Philimore, H., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12023 · Cited by 152
Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy
Fajardo, C. A., Guedan, S., Rojas, L. A., Moreno, R., Arias-Badia, M., de Sostoa, J., June, C. H., & Alemany, R. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1708 · Cited by 166
Seidensticker, R., Denecke, T., Kraus, P., Seidensticker, M., Mohnike, K., Fahlke, J., Kettner, E., Hildebrandt, B., Dudeck, O., Pech, M., et al. (2011) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-011-0234-7 · Cited by 158
“However, overall survivals with radioembolization compare favorably with recent studies in mCRC using new biological agents where median overall survival were 6.1 months with cetuximab versus 4.6 months with BSC (after 80% of patients had received C3 lines of chemotherapy) and 6.4 months with panitumumab versus simila…”
ResultInfluentialAdverse Events Associated with Anti-EGFR Therapies for the Treatment of Metastatic Colorectal Cancer
Fakih, M., & Vincent, M. (2010) · Current Oncology · doi:10.3747/co.v17is1.615 · Cited by 109
Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy
Shah, D. R., Shah, R. R., & Morganroth, J. (2013) · Drug Safety · doi:10.1007/s40264-013-0050-x · Cited by 160
“For example, skin toxicity has been consistently linked with higher response rates and longer survival among patients with metastatic colorectal cancer who have been treated with cetuximab [85], whereas patients without rash appear to have a poor outcome.”
BackgroundOsio, A., Mateus, C., Soria, J., Massard, C., Malka, D., Boige, V., Besse, B., & Robert, C. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09214.x · Cited by 150
Petrelli, F., Borgonovo, K., Cabiddu, M., Lonati, V., & Barni, S. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.06.009 · Cited by 156
KRAS Mutation in Colon Cancer: A Marker of Resistance to EGFR-I Therapy
Siddiqui, A. D., & Piperdi, B. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0811-z · Cited by 163
Saad, E. D., Katz, A., Hoff, P. M., & Buyse, M. E. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp523 · Cited by 159
Tanaka, N., Sakamoto, K., Okabe, H., Fujioka, A., Yamamura, K., Nakagawa, F., Nagase, H., Yokogawa, T., Oguchi, K., Ishida, K., et al. (2014) · Oncology Reports · doi:10.3892/or.2014.3487 · Cited by 149
Role of bile acids in colon carcinogenesis
Nguyen, T. T., Ung, T. T., Kim, N. H., & Jung, Y. D. (2018) · World Journal of Clinical Cases · doi:10.12998/wjcc.v6.i13.577 · Cited by 143
Current status of immunotherapy in metastatic colorectal cancer
Wróbel, P., & Ahmed, S. (2018) · International Journal of Colorectal Disease · doi:10.1007/s00384-018-3202-8 · Cited by 148
Mechanisms of resistance to HER family targeting antibodies
Kruser, T. J., & Wheeler, D. L. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.01.009 · Cited by 156
Targeting EGFR in Colorectal Cancer
Messersmith, W. A., & Ahnen, D. J. (2008) · New England Journal of Medicine · doi:10.1056/nejme0806778 · Cited by 156
Pinto, C., Fabio, F. D., Barone, C. A., Siena, S., Falcone, A., Cascinu, S., Llimpe, F. L. R., Stella, G. M., Schinzari, G., Artale, S. A., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605319 · Cited by 142
Ocular Toxicity of Targeted Therapies
Renouf, D. J., Velazquez-Martin, J. P., Simpson, R., Siu, L. L., & Bedard, P. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.5851 · Cited by 139
Lunenburg, C. A. T. C., Henricks, L. M., Guchelaar, H., Swen, J. J., Deenen, M. J., Schellens, J. H. M., & Gelderblom, H. A. J. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.008 · Cited by 139
Reidy, D. L., Vakiani, E., Fakih, M. G., Saif, M. W., Hecht, J. R., Goodman-Davis, N., Hollywood, E., Shia, J., Schwartz, J., Chandrawansa, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.4154 · Cited by 138
Gollins, S., Moran, B. J., Adams, R., Cunningham, C., Bach, S. P., Myint, A. S., Renehan, A. G., Karandikar, S. S., Goh, V., Prezzi, D., et al. (2017) · Colorectal Disease · doi:10.1111/codi.13705 · Cited by 153
Zhang, W., Winder, T., Ning, Y., Pohl, A. C., Yang, D., Kahn, M. R., Lurje, G., LaBonte, M. J., Wilson, P. M., Gordon, M. A., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq315 · Cited by 143
Self-citationMittmann, N., Au, H., Tu, D., O'Callaghan, C. J., Isogai, P. K., Karapetis, C. S., Zalcberg, J. R., Evans, W. K., Moore, M. J., Siddiqui, J., et al. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp232 · Cited by 144
Self-citationHan, S.-W., Oh, D.-Y., Im, S., Park, S. R., Lee, K.-W., SONG, H. S., Lee, N. S., Lee, K. H., Choi, I. S., Lee, M. H., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604861 · Cited by 137
Melosky, B. L., Burkes, R. L., Rayson, D., Alcindor, T., Shear, N. H., & Lacouture, M. E. (2009) · Current Oncology · doi:10.3747/co.v16i1.361 · Cited by 146
Vogel, A., Hofheinz, R. D., Kubicka, S., & Arnold, D. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.04.007 · Cited by 134
An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative Review
Fornasier, G., Francescon, S., & Baldo, P. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0791-0 · Cited by 134
American Society of Clinical Oncology 2013 Top Five List in Oncology
Schnipper, L. E., Lyman, G. H., Blayney, D. W., Hoverman, J. R., Raghavan, D., Wollins, D. S., & Schilsky, R. L. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.3943 · Cited by 136
Trivedi, S., Srivastava, R. M., Concha‐Benavente, F., Ferrone, S., García-Bates, T. M., Li, J., & Ferris, R. L. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2971 · Cited by 143
Environmental and Molecular Drivers of the α-Gal Syndrome
Cabezas-Cruz, A., Hodžić, A., Román-Carrasco, P., Mateos-Hernández, L., Duscher, G. G., Sinha, D. K., Hemmer, W., Swoboda, I., Estrada-Peña, A., & de la Fuente, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01210 · Cited by 131
Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer
Underwood, P. W., Ruff, S. M., & Pawlik, T. M. (2024) · Cells · doi:10.3390/cells13030245 · Cited by 130
“[14].”
BackgroundMostert, B., Jiang, Y., Sieuwerts, A. M., Wang, H., Bolt‐de Vries, J., Biermann, K., Kraan, J., Lalmahomed, Z., van Galen, A., de Weerd, V., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.27987 · Cited by 130
Van Cutsem, E., Tejpar, S., Vanbeckevoort, D., Peeters, M., Humblet, Y., Gelderblom, H., Vermorken, J. B., Viret, F., Glimelius, B., Gallerani, E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.9243 · Cited by 132
Suto, T., Yokobori, T., Yajima, R., Morita, H., Fujii, T., Yamaguchi, S., Altan, B., Tsutsumi, S., Asao, T., & Kuwano, H. (2015) · Carcinogenesis · doi:10.1093/carcin/bgu242 · Cited by 125
Response to Anti-EGFR Therapy in Patients with BRAF non-V600–Mutant Metastatic Colorectal Cancer
Yaeger, R., Kotani, D., Mondaca, S., Parikh, A. R., Bando, H., Van Seventer, E. E., Taniguchi, H., Zhao, H., Thant, C. N., de Stanchina, E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2004 · Cited by 125
EGFR and KRAS in Colorectal Cancer
Markman, B., Ramos, F. J., Capdevila, J., & Tabernero, J. M. (2010) · Advances in clinical chemistry · doi:10.1016/s0065-2423(10)51004-7 · Cited by 147
Macedo, L. T., da Costa Lima, A. B., & Sasse, A. D. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-89 · Cited by 126
Siu, L. L., Shapiro, J. D., Jonker, D. J., Karapetis, C. S., Zalcberg, J. R., Simes, J., Couture, F., Moore, M. J., Price, T. J., Siddiqui, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.0543 · Cited by 126
Self-citationProteomic Identification of Cysteine Cathepsin Substrates Shed from the Surface of Cancer Cells
Sobotič, B., Vizovišek, M., Vidmar, R., Van Damme, P., Gocheva, V., Joyce, J. A., Gevaert, K., Turk, V., Turk, B., & Fonović, M. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.044628 · Cited by 124
Bevacizumab-Induced Normalization of Blood Vessels in Tumors Hampers Antibody Uptake
Arjaans, M., Oude Munnink, T. H., Oosting, S. F., Terwisscha van Scheltinga, A. G. T., Gietema, J. A., Garbacik, E. T., Timmer-Bosscha, H., Lub-de Hooge, M. N., Schröder, C. P., & de Vries, E. G. E. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3518 · Cited by 121
Blick, S. K. A., & Scott, L. J. (2007) · Drugs · doi:10.2165/00003495-200767170-00008 · Cited by 126
Antibody-Mediated Delivery of Anti– KRAS -siRNA In Vivo Overcomes Therapy Resistance in Colon Cancer
Bäumer, S., Bäumer, N., Appel, N., Terheyden, L., Fremerey, J., Schelhaas, S., Wardelmann, E., Buchholz, F., Berdel, W. E., & Müller-Tidow, C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2017 · Cited by 119
Pinto, C., Barone, C. A., Girolomoni, G., Russi, E. G., Merlano, M. C., Ferrari, D., & Maiello, E. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0298 · Cited by 129
A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome
Snowsill, T., Huxley, N., Hoyle, M., Jones-Hughes, T., Coelho, H. F., Cooper, C., Frayling, I. M., & Hyde, C. (2014) · Health Technology Assessment · doi:10.3310/hta18580 · Cited by 132
Dwane, L., Behan, F. M., Gonçalves, E., Lightfoot, H., Yang, W., van der Meer, D., Shepherd, R., Pignatelli, M., Iorio, F., & Garnett, M. J. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa882 · Cited by 120
“For example, targeting HER2 with trastuzumab in breast cancer (1), mutant BRAF with vemurafenib in melanoma (2) and EGFR with cetuximab in colorectal cancer (3) has transformed patient outcomes since their introduction into the clinic.”
BackgroundPetrelli, F., Borgonovo, K., & Barni, S. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0257-x · Cited by 132
Targeted therapy in metastatic colorectal cancer – An example of personalised medicine in action
Heinemann, V., Douillard, J. Y., Ducreux, M., & Peeters, M. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.12.011 · Cited by 120
Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer
Knickelbein, K., & Zhang, L. (2015) · Genes & Diseases · doi:10.1016/j.gendis.2014.10.002 · Cited by 117
Master protocol trials in oncology: Review and new trial designs
Hirakawa, A., Asano, J., Sato, H., & Teramukai, S. (2018) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2018.08.009 · Cited by 131
Oncogenic mutations as predictive factors in colorectal cancer
Lièvre, A., Blons, H., & Laurent-Puig, P. (2010) · Oncogene · doi:10.1038/onc.2010.89 · Cited by 117
“A similarly designed randomized controlled trial performed by the National Cancer Institute of Canada-Clinical Trial Group (NCI-CCTG) included 572 chemorefractory patients to receive cetuximab in monotherapy or best supportive care (Jonker et al., 2007).”
BackgroundMethodGatzemeier, U., von Pawel, J., Vynnychenko, I. O., Zatloukal, P., de Marinis, F., Eberhardt, W., Paz-Ares, L. G., Schumacher, K.-M., Goddemeier, T., O'Byrne, K. J., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70278-3 · Cited by 120
Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer
Chan, D. L. H., Segelov, E., Wong, R. S., Smith, A., Herbertson, R. A., Li, B. T., Tebbutt, N., Price, T., & Pavlakis, N. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007047.pub2 · Cited by 114
Self-citationItaliano, A., Hostein, I., Soubeyran, I., Fabas, T., Benchimol, D., Evrard, S., Gugenheim, J., Becouarn, Y., Brunet, R., Fonck, M., et al. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0864-z · Cited by 114
Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers
Harandi, A., Zaidi, A. S., Stocker, A. M., & Laber, D. A. (2009) · Journal of Oncology · doi:10.1155/2009/567486 · Cited by 116
Tumor control versus adverse events with targeted anticancer therapies
Keefe, D. M. K., & Bateman, E. H. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.192 · Cited by 121
Toda, K., Kawada, K., Iwamoto, M., Inamoto, S., Sasazuki, T., Shirasawa, S., Hasegawa, S., & Sakai, Y. (2016) · Neoplasia · doi:10.1016/j.neo.2016.09.004 · Cited by 113
Treatment in advanced colorectal cancer: what, when and how?
Chau, I., & Cunningham, D. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605061 · Cited by 121
Au, H., Karapetis, C. S., O’Callaghan, C. J., Tu, D., Moore, M. J., Zalcberg, J. R., Kennecke, H. F., Shapiro, J. D., Koski, S. L., Pavlakis, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6048 · Cited by 115
Self-citationPreferences for cancer treatments: an overview of methods and applications in oncology
Blinman, P. L., King, M. T., Norman, R., Viney, R. C., & Stockler, M. R. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr559 · Cited by 127
Tabernero, J., Cervantes, A., Rivera, F., Martinelli, E., Rojo, F., von Heydebreck, A., Macarulla, T., Rodriguez-Braun, E., Eugenia Vega-Villegas, M., Senger, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6043 · Cited by 110
When are ‘positive’ clinical trials in oncology truly positive?
Ocana, A., & Tannock, I. F. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq463 · Cited by 110
Weickhardt, A. J., Price, T. J., Chong, G., Gebski, V., Pavlakis, N., Johns, T. G., Azad, A., Skrinos, E., Fluck, K., Dobrovic, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.6599 · Cited by 108
Self-citationCancers in Taiwan: Practical insight from epidemiology, treatments, biomarkers, and cost
Kuo, C.-N., Liao, Y., Kuo, L., Tsai, H., Chang, W., & Yen, Y. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2019.08.023 · Cited by 113
on behalf of the Australasian Gastro-Intestinal Trials Group, Tebbutt, N. C., Cummins, M. M., Sourjina, T., Strickland, A. H., van Hazel, G., Ganju, V., Gibbs, D. D., Stockler, M. R., Gebski, V., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605522 · Cited by 113
Self-citationBendell, J. C., Nemunaitis, J. J., Vukelja, S. J., Hagenstad, C. T., Campos, L. T., Hermann, R. C., Sportelli, P., Gardner, L. R., & Richards, D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1980 · Cited by 117
Prince, J. F., van den Bosch, M. A. A. J., Nijsen, J. F. W., Smits, M. L. J., van den Hoven, A. F., Nikolakopoulos, S., Wessels, F. J., Bruijnen, R. C. G., Braat, M. N. G. J. A., Zonnenberg, B. A., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.197194 · Cited by 116
Voigt, M., Braig, F., Göthel, M., Schulte, A., Lamszus, K., Bokemeyer, C., & Binder, M. (2012) · Neoplasia · doi:10.1593/neo.121242 · Cited by 106
Seruga, B., Sterling, L., Wang, L., & Tannock, I. F. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.9624 · Cited by 106
A Phase II Trial of Erlotinib in Recurrent Squamous Cell Carcinoma of the Cervix
Schilder, R. J., Sill, M. W., Lee, Y.-C., & Mannel, R. S. (2009) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181a83467 · Cited by 107
Cheng, F., Jia, P., Wang, Q., & Zhao, Z. (2014) · Oncotarget · doi:10.18632/oncotarget.1984 · Cited by 110
Schneider, M. A., Eden, J., Pache, B. C.-E., Laminger, F., López‐López, V., Steffen, T., Hübner, M., Kober, F., Roka, R., Campos, P. C., et al. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002899 · Cited by 111
“They modestly improve overall- and recurrence-free survival (RFS), when given alone or in combination with standard regimens.(16,17) In patients with PM of colorectal origin, the role of RAS/RAF mutations has not been examined and might be helpful to predict survival after CRS/HIPEC in combination with other prognosti…”
MethodChan, J. A.-W., Blaszkowsky, L. S., Enzinger, P. C., Ryan, D. P., Abrams, T. A., Zhu, A. X., Temel, J. S., Schrag, D., Bhargava, P., Meyerhardt, J. A., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq604 · Cited by 105
Yap, T. A., & Workman, P. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134532 · Cited by 106
Kirstein, M. M., Lange, A., Prenzler, A., Manns, M. P., Kubicka, S., & Vogel, A. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0032 · Cited by 112
20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight
Singh, S. K., Sadhukhan, S., & Sonawane, A. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188967 · Cited by 117
Advances in the management of colorectal cancer: from biology to treatment
Ahmed, S., JOHNSON, K., Ahmed, O., & Iqbal, N. (2014) · International Journal of Colorectal Disease · doi:10.1007/s00384-014-1928-5 · Cited by 117
Kawada, K., Nakamoto, Y., Kawada, M., Hida, K., Matsumoto, T., Murakami, T., Hasegawa, S., Togashi, K., & Sakai, Y. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1909 · Cited by 104
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence
Troiani, T., Napolitano, S., Della Corte, C. M., Martini, G., Martinelli, E., Morgillo, F., & Ciardiello, F. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000088 · Cited by 104
Metronomic chemotherapy for cancer treatment: a decade of clinical studies
Romiti, A., Cox, M. C., Sarcina, I., Rocco, R. D., D’Antonio, C., Barucca, V., & Marchetti, P. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2125-x · Cited by 112
Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R.
Patel, B. B., Gupta, D., Elliott, A. A., Sengupta, V., Yu, Y., & Majumdar, A. P. N. (2010) · PubMed · Cited by 111
Au, H.-J., Ringash, J., Brundage, M., Palmer, M., Richardson, H., & Meyer, R. M. (2010) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.10.15 · Cited by 104
Self-citationManning, H. C., Merchant, N. B., Foutch, A. C., Virostko, J. M., Wyatt, S. K., Shah, C., McKinley, E. T., Xie, J., Mutic, N. J., Washington, M. K., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0239 · Cited by 105
Activation of Tumor-Promoting Type 2 Macrophages by EGFR-Targeting Antibody Cetuximab
Pander, J., Heusinkveld, M., van der Straaten, T., Jordanova, E. S., Baak-Pablo, R., Gelderblom, H., Morreau, H., van der Burg, S. H., Guchelaar, H.-J., & van Hall, T. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0239 · Cited by 101
Metadata
- Authors
- Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., Tebbutt, N. C., van Hazel, G., Wierzbicki, R., Langer, C., & Moore, M. J.
- Affiliations
- University of Ottawa (CA)
- Flinders Medical Centre (AU)
- The University of Melbourne (AU)
- Queen's University (CA)
- Cross Cancer Institute (CA)
- Sunnybrook Health Science Centre (CA)
- St. Boniface Hospital (CA)
- Queen Elizabeth Hospital (AU)
- The University of Sydney (AU)
- Austin Health (AU)
- Lakeridge Health (CA)
- Bristol-Myers Squibb (United States) (US)
- Princess Margaret Cancer Centre (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-15
- Volume
- 357
- Issue
- 20
- Pages
- 2040-2048
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2115790682
- Cited by
- 1,904
- References
- 20
- Citations by year
- 2026: 23 · 2025: 47 · 2024: 56 · 2023: 60 · 2022: 62 · 2021: 63 · 2020: 87 · 2019: 82 · 2018: 84 · 2017: 101 · 2016: 110 · 2015: 133 · 2014: 143 · 2013: 150 · 2012: 153
- FWCI
- 68.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- cetuximab, colorectal cancer, epidermal growth factor receptor, EGFR-positive tumors, monoclonal antibody therapy, best supportive care, overall survival, progression-free survival, rash, quality of life, adverse events, irinotecan, oxaliplatin, fluoropyrimidine
- MeSH terms
- Cetuximab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Exanthema, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Colorectal Neoplasms, Survival Analysis, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.